As of Jun 18
| +0.02 / +0.04%|
The 4 analysts offering 12-month price forecasts for Anika Therapeutics Inc have a median target of 52.50, with a high estimate of 71.00 and a low estimate of 39.00. The median estimate represents a +16.49% increase from the last price of 45.07.
The current consensus among 4 polled investment analysts is to Buy stock in Anika Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.